316
Participants
Start Date
September 30, 2021
Primary Completion Date
June 14, 2023
Study Completion Date
December 31, 2025
LOXO-338
Oral
Pirtobrutinib
Oral
Memorial Sloan Kettering Cancer Center, New York
Emory University, Atlanta
L'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse
Mayo Clinic in Florida, Jacksonville
Sylvester Comprehensive Cancer Center, Miami
Centre hospitalier universitaire de Haut Leveque, Pessac
CHRU de Montpellier-Hopital St Eloi, Montpellier
IRCCS - AOU di Bologna, Bologna
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes
Indiana Blood & Marrow Transplantation (IBMT), Indianapolis
Medical College of Wisconsin, Milwaukee
University of Kansas Medical Center, Westwood
Centre Hospitalier Lyon Sud, Pierre-Bénite
Institut Curie, Paris
The University of Arizona Cancer Center, Tucson
University of California San Francisco, Medical Center at Paranassus, San Francisco
Swedish Medical Center, Seattle
City of Hope National Medical Center, Duarte
Tufts Medical Center, Boston
Mayo Clinic, Rochester
Centrum Medyczne Pratia Poznan, Skorzewo
Pratia MCM Krakow, Krakow
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warsaw
Eli Lilly and Company
INDUSTRY